| pubmed-article:9676843 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9676843 | lifeskim:mentions | umls-concept:C0043210 | lld:lifeskim |
| pubmed-article:9676843 | lifeskim:mentions | umls-concept:C0870134 | lld:lifeskim |
| pubmed-article:9676843 | lifeskim:mentions | umls-concept:C0229664 | lld:lifeskim |
| pubmed-article:9676843 | lifeskim:mentions | umls-concept:C0278488 | lld:lifeskim |
| pubmed-article:9676843 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:9676843 | lifeskim:mentions | umls-concept:C0025241 | lld:lifeskim |
| pubmed-article:9676843 | lifeskim:mentions | umls-concept:C0039871 | lld:lifeskim |
| pubmed-article:9676843 | lifeskim:mentions | umls-concept:C0079083 | lld:lifeskim |
| pubmed-article:9676843 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
| pubmed-article:9676843 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:9676843 | lifeskim:mentions | umls-concept:C1317973 | lld:lifeskim |
| pubmed-article:9676843 | lifeskim:mentions | umls-concept:C0183683 | lld:lifeskim |
| pubmed-article:9676843 | lifeskim:mentions | umls-concept:C0344211 | lld:lifeskim |
| pubmed-article:9676843 | lifeskim:mentions | umls-concept:C1521721 | lld:lifeskim |
| pubmed-article:9676843 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:9676843 | lifeskim:mentions | umls-concept:C1328050 | lld:lifeskim |
| pubmed-article:9676843 | lifeskim:mentions | umls-concept:C1705294 | lld:lifeskim |
| pubmed-article:9676843 | lifeskim:mentions | umls-concept:C1171411 | lld:lifeskim |
| pubmed-article:9676843 | lifeskim:mentions | umls-concept:C2003874 | lld:lifeskim |
| pubmed-article:9676843 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:9676843 | pubmed:dateCreated | 1998-9-16 | lld:pubmed |
| pubmed-article:9676843 | pubmed:abstractText | A single high-dose cycle of chemotherapy with stem cell support can produce disease-free survival of 15-20% for at least 3 years in women with responding stage IV breast cancer. North American Autologous Bone Marrow Transplant Registry data suggest that a complete response (CR) is the single most important prognostic factor associated with prolonged disease-free survival. Therefore, if sequential high-dose chemotherapy can increase the CR rate, then perhaps an increased proportion of patients will remain disease free. Women with at least a partial response (PR) to induction chemotherapy received three separate high-dose cycles of chemotherapy with peripheral blood progenitor support and granulocyte colony-stimulating factor. The first intensification was a dose escalation of paclitaxel (400-825 mg/ m2), the second intensification was melphalan (180 mg/m2), and the third intensification consisted of 6000 mg/m2 cyclophosphamide (1500 mg/m2/day), 500 mg/m2 thiotepa (125 mg/m2/day), and 800 mg/m2 carboplatin (200 mg/m2/day; CTCb). Thirty-six women were enrolled and 31 completed all three cycles. After the paclitaxel infusion most patients developed reversible predominantly sensory neuropathy. Of the 19 patients with measurable disease, 6 converted to CR, 7 converted to a PR* (the complete resolution of all soft tissue or visceral disease with sclerosis of prior lytic bone lesions), and 2 had a further PR for an overall response rate of 79%. Two patients had no further response and disease in two patients progressed, and thus they were taken off the study before CTCb. Seventy-eight percent are progression-free at a median follow-up of 14 months (range, 3-24+). Three sequential cycles of high-dose chemotherapy are feasible and were administered in this study with no mortality. Single agent paclitaxel at doses up to 825 mg/m2 were well tolerated with moderate reversible toxicity. | lld:pubmed |
| pubmed-article:9676843 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9676843 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9676843 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9676843 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9676843 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9676843 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9676843 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9676843 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9676843 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9676843 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9676843 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9676843 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9676843 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:9676843 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:9676843 | pubmed:author | pubmed-author:KaufmanEE | lld:pubmed |
| pubmed-article:9676843 | pubmed:author | pubmed-author:SavageDD | lld:pubmed |
| pubmed-article:9676843 | pubmed:author | pubmed-author:GarrettTT | lld:pubmed |
| pubmed-article:9676843 | pubmed:author | pubmed-author:FunkFF | lld:pubmed |
| pubmed-article:9676843 | pubmed:author | pubmed-author:PapadopoulouE... | lld:pubmed |
| pubmed-article:9676843 | pubmed:author | pubmed-author:McGovernTT | lld:pubmed |
| pubmed-article:9676843 | pubmed:author | pubmed-author:AntmanKK | lld:pubmed |
| pubmed-article:9676843 | pubmed:author | pubmed-author:AyelloJJ | lld:pubmed |
| pubmed-article:9676843 | pubmed:author | pubmed-author:HesdorfferCC | lld:pubmed |
| pubmed-article:9676843 | pubmed:author | pubmed-author:BagiellaEE | lld:pubmed |
| pubmed-article:9676843 | pubmed:author | pubmed-author:HeitjanDD | lld:pubmed |
| pubmed-article:9676843 | pubmed:author | pubmed-author:TierstenAA | lld:pubmed |
| pubmed-article:9676843 | pubmed:author | pubmed-author:BalmacedaCC | lld:pubmed |
| pubmed-article:9676843 | pubmed:author | pubmed-author:VahdatL TLT | lld:pubmed |
| pubmed-article:9676843 | pubmed:author | pubmed-author:DunleavyJJ | lld:pubmed |
| pubmed-article:9676843 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9676843 | pubmed:volume | 4 | lld:pubmed |
| pubmed-article:9676843 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9676843 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9676843 | pubmed:pagination | 1689-95 | lld:pubmed |
| pubmed-article:9676843 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:9676843 | pubmed:meshHeading | pubmed-meshheading:9676843-... | lld:pubmed |
| pubmed-article:9676843 | pubmed:meshHeading | pubmed-meshheading:9676843-... | lld:pubmed |
| pubmed-article:9676843 | pubmed:meshHeading | pubmed-meshheading:9676843-... | lld:pubmed |
| pubmed-article:9676843 | pubmed:meshHeading | pubmed-meshheading:9676843-... | lld:pubmed |
| pubmed-article:9676843 | pubmed:meshHeading | pubmed-meshheading:9676843-... | lld:pubmed |
| pubmed-article:9676843 | pubmed:meshHeading | pubmed-meshheading:9676843-... | lld:pubmed |
| pubmed-article:9676843 | pubmed:meshHeading | pubmed-meshheading:9676843-... | lld:pubmed |
| pubmed-article:9676843 | pubmed:meshHeading | pubmed-meshheading:9676843-... | lld:pubmed |
| pubmed-article:9676843 | pubmed:meshHeading | pubmed-meshheading:9676843-... | lld:pubmed |
| pubmed-article:9676843 | pubmed:meshHeading | pubmed-meshheading:9676843-... | lld:pubmed |
| pubmed-article:9676843 | pubmed:meshHeading | pubmed-meshheading:9676843-... | lld:pubmed |
| pubmed-article:9676843 | pubmed:meshHeading | pubmed-meshheading:9676843-... | lld:pubmed |
| pubmed-article:9676843 | pubmed:meshHeading | pubmed-meshheading:9676843-... | lld:pubmed |
| pubmed-article:9676843 | pubmed:meshHeading | pubmed-meshheading:9676843-... | lld:pubmed |
| pubmed-article:9676843 | pubmed:meshHeading | pubmed-meshheading:9676843-... | lld:pubmed |
| pubmed-article:9676843 | pubmed:meshHeading | pubmed-meshheading:9676843-... | lld:pubmed |
| pubmed-article:9676843 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9676843 | pubmed:articleTitle | Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. | lld:pubmed |
| pubmed-article:9676843 | pubmed:affiliation | Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA. | lld:pubmed |
| pubmed-article:9676843 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9676843 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9676843 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:9676843 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:9676843 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9676843 | lld:pubmed |
